Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Metformin on Cell Kinetic Parameters of MCF-7 Breast Cancer Cells in Vitro

  • Topcul, Mehmet (Department of Biology, Faculty of Science, Istanbul University) ;
  • Cetin, Idil (Department of Biology, Faculty of Science, Istanbul University)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

In this study, the antiproliferative effects of the metformin was evaluated on MCF-7 Cells (human breast adenocarcinoma cell line). For this purpose cell kinetic parameters including cell proliferation assay, mitotic index and labelling index analysis were used. $30{\mu}M$, $65{\mu}M$ and $130{\mu}M$ Metformin doses were applied to cells for 24, 48 and 72 hours. The results showed that there was a significant decrease in cell proliferation, mitotic index and labelling index for all experimental groups (p<0.05) for all applications.

Keywords

References

  1. Bao B, Wang Z, Ali S, et al (2012). Metformin inhibits cell proliferation, migration and invasion by attenuating csc function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res, 5, 355-64. https://doi.org/10.1158/1940-6207.CAPR-11-0299
  2. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006). Increased cancerrelated mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29, 254-8. https://doi.org/10.2337/diacare.29.02.06.dc05-1558
  3. Cairns RA, Harris IS, Mak TW (2011). Regulation of cancer cell metabolism. Nat Rev Cancer, 11, 85-95. https://doi.org/10.1038/nrc2981
  4. Calle EE, Kaaks R (2004). Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 4, 579-91. https://doi.org/10.1038/nrc1408
  5. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A (2009). Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev, 18, 701-5. https://doi.org/10.1158/1055-9965.EPI-08-0871
  6. Cetin I, Topcul M (2012). Cancer stem cells in oncology. J BUON, 17, 644-8.
  7. Cetin I, Topcul M (2014). Triple negative breast cancer. Asian Pac J Cancer Prev, 15, 2427- 31. https://doi.org/10.7314/APJCP.2014.15.6.2427
  8. Costa D, Gigoni A, Wurth R, et al (2014). Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA. Cancer Cell International, 14, 59. https://doi.org/10.1186/1475-2867-14-59
  9. Cusi K, Consoli A, DeFronzo RA (1996). Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 81, 4059-67.
  10. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 7, 11-20. https://doi.org/10.1016/j.cmet.2007.10.002
  11. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res, 67, 10804-12. https://doi.org/10.1158/0008-5472.CAN-07-2310
  12. Dowling RJO, Goodwin PJ, Stambolic V (2011). Understanding the benefit of metformin use in cancer treatment. BMC Medicine, 9, 33. https://doi.org/10.1186/1741-7015-9-33
  13. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5. https://doi.org/10.1136/bmj.38415.708634.F7
  14. Goodwin PJ, Stambolic V, Lemieux J, et al (2011). Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat, 126, 215-20. https://doi.org/10.1007/s10549-010-1224-1
  15. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11. https://doi.org/10.1158/0008-5472.CAN-09-2994
  16. Koppenol WH, Bounds PL, Dang CV (2011). Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 11, 325-37. https://doi.org/10.1038/nrc3038
  17. Kourelis TV, Siegel RD (2012). Metformin and cancer: new applications for an old drug. Med Oncol, 29, 1314-27. https://doi.org/10.1007/s12032-011-9846-7
  18. Larsson SC, Mantzoros CS, Wolk A (2007). Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer, 121, 856 -62. https://doi.org/10.1002/ijc.22717
  19. Pollak MN, Schernhammer ES, Hankinson SE (2004). Insulin-like growth factors and neoplasia. Nat Rev Cancer, 4, 505-18. https://doi.org/10.1038/nrc1387
  20. Renehan AG, Frystyk J, Flyvbjerg A (2006). Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab, 17, 328-36. https://doi.org/10.1016/j.tem.2006.08.006
  21. Sun XJ, Zhang P, Li HH, Jiang ZW, et al (2014). Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating e-cadherin and mmp-9. Asian Pac J Cancer Prev, 15, 4019-23. https://doi.org/10.7314/APJCP.2014.15.9.4019
  22. Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M, Bidadi S (2014). Antiproliferative effect of metformin on the endometrium - a clinical trial. Asian Pac J Cancer Prev, 15, 10067-70.
  23. Topcul M, Topcul F, Cetin I (2013). Effects of femara and tamoxifen on proliferation of FM3A cells in culture. Asian Pac J Cancer Prev, 14, 2819-22. https://doi.org/10.7314/APJCP.2013.14.5.2819
  24. Vander Heiden MG (2011). Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov, 10, 671-84. https://doi.org/10.1038/nrd3504
  25. Vander Heiden MG, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-33. https://doi.org/10.1126/science.1160809
  26. Ward PS, Thompson CB (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell, 21, 297-308. https://doi.org/10.1016/j.ccr.2012.02.014
  27. Witters LA (2001). The blooming of the French lilac. J Clin Invest, 108, 1105-7. https://doi.org/10.1172/JCI14178
  28. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B (2005). Diabetes mellitus and breast cancer. Lancet Oncol, 6, 103-11. https://doi.org/10.1016/S1470-2045(05)01736-5
  29. Xiong Y, Lu QJ, Zhao J, Wu GY (2012). Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev, 13, 3275-79. https://doi.org/10.7314/APJCP.2012.13.7.3275
  30. Yee D (2006). Targeting insulin-like growth factor pathways. Br J Cancer, 94, 465-8. https://doi.org/10.1038/sj.bjc.6602963

Cited by

  1. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6973
  2. Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis vol.9, pp.4, 2017, https://doi.org/10.1177/1758834016687482